Last updated: July 12, 2026
Xeris Pharmaceuticals, Inc. has sued Novitium Pharma, LLC in the Northern District of Illinois under case number 2:26-cv-06568. The matter’s litigation posture, asserted patent(s), and claim construction themes are not stated in the available input, so a complete, accurate infringement/invalidity analysis cannot be produced from the provided information alone.
What is the case status for Xeris Pharmaceuticals v. Novitium (2:26-cv-06568)?
- No docket outcomes, motions, hearing dates, scheduling order milestones, or final judgment information is provided in the input.
Which patents does Xeris assert against Novitium in 2:26-cv-06568?
- The complaint’s asserted Orange Book patents, patent numbers, expiration dates, and claim(s)-at-issue are not included in the input.
What drug product and ANDA/BLA regulatory pathway triggered the lawsuit?
- The specific litigated product, the reference listed drug (RLD), the ANDA number, or the Paragraph IV basis are not provided.
What is Novitium’s response posture in 2:26-cv-06568 (motions, defenses, invalidity theories)?
- The input does not include Novitium’s answer, Rule 12 motions, invalidity contentions, or written-description/enablement positions.
How strong is Xeris’s patent estate for this specific dispute?
- Patent strength analysis requires the asserted patents, independent/dependent claim structure, prosecution history, and claim limitations at issue. None of this is present in the input.
When does exclusivity expire for the litigated Xeris product, and what launch timelines are at risk?
- Exclusivity timelines depend on the RLD’s exclusivity grants (3-year, 5-year, orphan if applicable) and Orange Book patent expiration. Those identifiers and dates are not provided.
What is the Orange Book status for the RLD tied to 2:26-cv-06568?
- Orange Book listing status (listed patents, status code, expiration dates) is not included in the input.
What formulation, method-of-use, or device claims are implicated?
- The input contains no claim categories or dosage-form information needed to map infringement to formulation vs. method-of-use claims.
What generic entry risks exist for Novitium if Xeris’s asserted patents are upheld?
- Generic launch risk assessment requires the ANDA maturity, design-around details, and each asserted patent’s validity and enforceability posture.
What settlement or consent decree terms affect market entry?
- No settlement agreement, stipulation, or consent judgment terms are provided in the input.
How does this case compare with other Xeris v. generic manufacturer litigations?
- Comparison requires identified asserted patents, similar defendants, and outcomes across other cases; none are provided.
Key Takeaways
- The input confirms the existence of Xeris Pharmaceuticals, Inc. v. Novitium Pharma, LLC in case number 2:26-cv-06568.
- Litigation summary and patent-claims analysis cannot be completed because the input lacks the complaint and docket specifics needed to identify asserted patents, regulatory triggers, claim limitations, and procedural posture.
FAQs
- What is the litigation trigger for Xeris v. Novitium in 2:26-cv-06568 (ANDA, Paragraph IV, or other)?
- Which Orange Book patents are asserted in Xeris’s complaint?
- What procedural milestones (motions, claim construction, trial date) are scheduled in 2:26-cv-06568?
- What validity challenges has Novitium raised (35 U.S.C. §§ 102, 103, 112, 101, inequitable conduct)?
- If Xeris’s patents are upheld, what is the likely impact on Novitium’s proposed launch timing?
References
No sources were provided in the input.
